VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-03

Reporting Person: Arbuckle Stuart A (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-03	Common Stock	A	8438	$0.00	Acquired	43617	Direct
2021-02-03	Common Stock	A	12388	$0.00	Acquired	56005	Direct
2021-02-03	Common Stock	A	13952	$0.00	Acquired	69957	Direct
2021-02-03	Common Stock	M	1554	$86.52	Acquired	71511	Direct
2021-02-03	Common Stock	S	148	$211.22	Disposed	71363	Direct
2021-02-03	Common Stock	S	488	$212.77	Disposed	70875	Direct
2021-02-03	Common Stock	S	497	$213.90	Disposed	70378	Direct
2021-02-03	Common Stock	S	242	$214.98	Disposed	70136	Direct
2021-02-03	Common Stock	S	90	$215.80	Disposed	70046	Direct
2021-02-03	Common Stock	S	89	$216.83	Disposed	69957	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Stock Option (Right to Buy)	$86.52	M	1554	Disposed	2027-02-02	Common Stock (1554)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.

F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.

F3: Restricted stock unit award that vests in installments beginning on 02/17/2022.

F4: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F5: Open market sales reported on this line occurred at a weighted average price of $211.22 (range $211.06 to $211.27).

F6: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F7: Open market sales reported on this line occurred at a weighted average price of $212.77 (range $212.29 to $213.20).

F8: Open market sales reported on this line occurred at a weighted average price of $213.90 (range $213.49 to $214.17).

F9: Open market sales reported on this line occurred at a weighted average price of $214.98 (range $214.72 to $215.36).

F10: Fully vested.